SLC5A2 and heart failure: The prior network meta-analysis2 showed that, in addition to major adverse cardiovascular events, use of SGLT2 inhibitors and GLP-1 receptor agonists reduced the risk of admission to the hospital for heart failure and reduced the risk of end-stage kidney disease, with superior efficacy with use of SGLT2 inhibitors in reducing end-stage kidney disease.